A Safety Study of SGN-CD19A for Leukemia and Lymphoma

NCT01786096 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Burkitt Lymphoma
Precursor B-cell Lymphoblastic Leukemia-Lymphoma

Interventions

DRUG: SGN-CD19A

Sponsor

Seagen Inc.